Pasithea Therapeutics Corp. (KTTA)
USD 2.54
(-4.51%)
USD 2.54
(-4.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | 486.55 Thousand | 15.06 Thousand | - |
| Cost of Revenue | 648.45 Thousand | 113.19 Thousand | 17.27 Thousand | - |
| Gross Profit | -648.45 Thousand | 373.36 Thousand | -2213.00 | - |
| Operating Expenses | 15.97 Million | 15.18 Million | 4.5 Million | 40.98 Thousand |
| Selling, General and Administrative Expenses | 7.87 Million | 12.52 Million | 4.5 Million | 40.98 Thousand |
| Research and Development Expenses | 8.1 Million | 2.66 Million | - | - |
| Other Expenses | - | 44.72 Thousand | - | - |
| Cost and Expenses | 15.97 Million | 15.3 Million | 4.52 Million | 40.98 Thousand |
| Operating Income | -15.97 Million | -14.81 Million | -4.5 Million | -40.98 Thousand |
| Interest Expense | - | 102.00 | 508.00 | - |
| Income Tax Expense | - | -879.97 Thousand | 508.00 | -61.47 Thousand |
| Earnings before Tax | -15.5 Million | -13.93 Million | -2.17 Million | -40.98 Thousand |
| Net Income | -15.96 Million | -13.05 Million | -2.17 Million | -40.98 Thousand |
| Earnings Per Share Basic | -12.65 | -10.34 | -1.89 | -0.06 |
| Earnings Per Share Diluted | -13.01 | -10.34 | -1.89 | -0.06 |
| Weighted Average Shares Outstanding | 1.26 Million | 1.26 Million | 1.15 Million | 688.91 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 1.22 Million | 1.26 Million | 1.15 Million | 688.91 Thousand |
| Gross Margin | - | 0.77 | -0.15 | - |
| EBIT Margin | - | -30.29 | -299.17 | - |
| Profit Margin | - | -26.83 | -144.34 | - |
| EBITDA | -15.33 Million | -12.58 Million | -4.5 Million | - |
| Earnings Before Tax Margin | - | -30.45 | -299.26 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 976.3 Thousand | - | - |
| Cost of Revenue | 162.25 Thousand | 162.25 Thousand | 648.45 Thousand | 162.22 Thousand | 162.25 Thousand | 163.21 Thousand |
| Gross Profit | -162.25 Thousand | -162.25 Thousand | -648.45 Thousand | 814.08 Thousand | -162.25 Thousand | -163.21 Thousand |
| Operating Expenses | 3.78 Million | 3.87 Million | 15.33 Million | 4.98 Million | 3.78 Million | 3.82 Million |
| Selling, General and Administrative Expenses | 1.42 Million | 2.12 Million | - | 1.63 Million | 2.16 Million | 1.8 Million |
| Research and Development Expenses | 2.35 Million | 1.74 Million | - | 3.35 Million | 1.62 Million | 2.02 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 3.94 Million | 4.04 Million | 15.97 Million | 5.14 Million | 3.78 Million | 3.82 Million |
| Operating Income | -3.94 Million | -4.04 Million | -15.97 Million | -5.14 Million | -3.78 Million | -3.82 Million |
| Interest Expense | - | - | - | -6388.00 | - | - |
| Income Tax Expense | 4.00 | 2.00 | 453.91 Million | 16.89 Thousand | -162.25 Thousand | -65.47 Thousand |
| Earnings before Tax | -3.86 Million | -3.86 Million | -15.5 Million | -5.03 Million | -3.61 Million | -3.59 Million |
| Net Income | -3.86 Million | -3.86 Million | -15.96 Million | -5.04 Million | -3.61 Million | -3.76 Million |
| Earnings Per Share Basic | -3.71 | -3.70 | - | -4.85 | -2.87 | -2.88 |
| Earnings Per Share Diluted | -3.71 | -3.70 | - | -4.85 | -2.87 | -2.88 |
| Weighted Average Shares Outstanding | 1.04 Million | 1.04 Million | 1.22 Million | 1.04 Million | 1.25 Million | 1.3 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.04 Million | 1.04 Million | 1.22 Million | 1.04 Million | 1.25 Million | 1.3 Million |
| Gross Margin | - | - | - | 0.83 | - | - |
| EBIT Margin | - | - | - | -5.11 | - | - |
| Profit Margin | - | - | - | -5.17 | - | - |
| EBITDA | -3.78 Million | -3.87 Million | - | -4.98 Million | -3.78 Million | -3.77 Million |
| Earnings Before Tax Margin | - | - | - | -5.27 | - | - |
6333
2404
CL
2185
600483
002383